London, UK, 8 April 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC:ATSMY) today announces the publication of data on the selective killing of breast cancer cells by Antisoma’s nucleolin-targeting aptamer AS1411. The work was carried out by Professor Daniel Fernandes and colleagues at the Medical University of South Carolina (MUSC) and is published in the April issue of the journal Cancer Research.
